Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-806 dose-ranging study in moderate to severe plaque psoriasis
2022-502249-90-00Phase 2Completed
- Sponsor
- DICE Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing DC-806 dose-ranging arms with Placebo (2 arms). Primary endpoints: PASI-75 at Week 12 and Safety events. Started Aug 2023; status: completed.
02
Drugs
navepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-502249-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502249-90-00.